Abstract Introduction: Romosozumab is a monoclonal antibody targeting sclerostin and is approved for the treatment of osteoporosis in postmenopausal women at high risk of fracture. SAL023 is a proposed biosimilar to romosozumab. For biosimilar development, a robust and unbiased anti-drug antibody (ADA) assay is required to support comparative immunogenicity assessment of the biosimilar and reference product.
Lei Geng
As seen in:
Nature,
Wiley Online Library,
arXiv,
Frontiers,
Frontiers in Immunology,
MDPI,
ACS Publications,
BMC Cancer,
Science Magazine,
Royal Society of Chemistry
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Lei
Contact Lei, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack